Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:EMMA NYSE:IBIO NASDAQ:LIPO NASDAQ:SLRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMMAEmmaus Life Sciences$0.01-9.2%$0.01$0.00▼$0.05$700K8.0329,742 shs323,580 shsIBIOiBio$0.82-0.9%$0.73$0.56▼$6.89$16.07M0.61.54 million shs563,945 shsLIPOLipella Pharmaceuticals$0.59-0.5%$0.71$0.55▼$7.31$2.74M-0.1852,959 shs1,095 shsSLRXSalarius Pharmaceuticals$5.76+1.4%$10.01$4.76▼$108.00$2.94M0.45137,916 shs40,754 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMMAEmmaus Life Sciences0.00%-12.80%-24.31%-45.23%+419.05%IBIOiBio0.00%+3.38%+20.25%+6.54%-57.41%LIPOLipella Pharmaceuticals0.00%-0.02%-15.82%-79.93%-83.11%SLRXSalarius Pharmaceuticals0.00%-0.17%-35.93%-50.77%-76.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEMMAEmmaus Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AIBIOiBio1.8835 of 5 stars3.50.00.00.02.80.00.6LIPOLipella PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASLRXSalarius Pharmaceuticals0.1196 of 5 stars0.02.00.00.02.60.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMMAEmmaus Life Sciences 0.00N/AN/AN/AIBIOiBio 3.00Buy$5.00511.47% UpsideLIPOLipella Pharmaceuticals 0.00N/AN/AN/ASLRXSalarius Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest EMMA, SLRX, LIPO, and IBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMMAEmmaus Life Sciences$16.65M0.04N/AN/A($0.87) per share-0.01IBIOiBio$375K42.86N/AN/A$1.41 per share0.58LIPOLipella Pharmaceuticals$536.36K5.08N/AN/A$1.59 per share0.37SLRXSalarius PharmaceuticalsN/AN/AN/AN/A($1.63) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMMAEmmaus Life Sciences-$6.45M-$0.10N/A∞N/A-24.20%N/A-14.00%N/AIBIOiBio-$24.91MN/A0.00N/AN/AN/A-73.15%-45.51%N/ALIPOLipella Pharmaceuticals-$5.02M-$3.43N/A∞N/A-988.83%-224.08%-172.88%N/ASLRXSalarius Pharmaceuticals-$5.58M-$43.48N/A∞N/AN/A-556.47%-192.35%11/12/2025 (Estimated)Latest EMMA, SLRX, LIPO, and IBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025EMMAEmmaus Life SciencesN/A-$0.02N/A-$0.02N/A$2.82 million8/12/2025Q2 2025SLRXSalarius Pharmaceuticals-$33.00-$0.45+$32.55-$0.45N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMMAEmmaus Life SciencesN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/ALIPOLipella PharmaceuticalsN/AN/AN/AN/AN/ASLRXSalarius PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMMAEmmaus Life SciencesN/A0.080.06IBIOiBio0.051.761.76LIPOLipella PharmaceuticalsN/A6.216.21SLRXSalarius PharmaceuticalsN/A0.610.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMMAEmmaus Life Sciences7.42%IBIOiBio7.90%LIPOLipella Pharmaceuticals74.31%SLRXSalarius Pharmaceuticals11.88%Insider OwnershipCompanyInsider OwnershipEMMAEmmaus Life Sciences35.00%IBIOiBio0.58%LIPOLipella Pharmaceuticals32.11%SLRXSalarius Pharmaceuticals1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEMMAEmmaus Life Sciences6063.87 million41.51 millionNot OptionableIBIOiBio10019.66 million9.82 millionN/ALIPOLipella Pharmaceuticals44.62 million3.03 millionNot OptionableSLRXSalarius Pharmaceuticals20510,000504,000Not OptionableEMMA, SLRX, LIPO, and IBIO HeadlinesRecent News About These CompaniesSalarius Pharmaceuticals Files Prospectus for Stock OfferingAugust 27, 2025 | msn.comSalarius Pharmaceuticals (NASDAQ:SLRX) Stock Rating Upgraded by Wall Street ZenAugust 24, 2025 | americanbankingnews.comSalarius Pharmaceuticals Inc (SLRX) - Investing.comAugust 20, 2025 | investing.comSalarius Pharmaceuticals Appoints New Acting CEOAugust 19, 2025 | msn.comSalarius Pharmaceuticals files $50M mixed securities shelfAugust 16, 2025 | msn.comSalarius Pharmaceuticals trading halted, news pendingAugust 16, 2025 | msn.comSalarius Pharmaceuticals Announces Reverse Stock SplitAugust 16, 2025 | msn.comSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock SplitAugust 14, 2025 | finanznachrichten.deSalarius Pharmaceuticals Announces 1-for-15 Reverse Stock SplitAugust 14, 2025 | globenewswire.comSalarius Pharmaceuticals Raises $3.8M Through Stock SaleJuly 31, 2025 | msn.comSalarius Pharmaceuticals Modifies Security Holders’ RightsJuly 30, 2025 | msn.comSalarius Pharmaceuticals stock soars after Nasdaq extends compliance deadlineJuly 29, 2025 | investing.comSalarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity StandardJuly 14, 2025 | finance.yahoo.comSalarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity StandardJuly 14, 2025 | globenewswire.comSalarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role ...July 11, 2025 | morningstar.comMSalarius Pharmaceuticals shareholders approve reverse stock split and share issuanceJuly 10, 2025 | uk.investing.comSalarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published StudiesJuly 10, 2025 | finance.yahoo.comSalarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published StudiesJuly 9, 2025 | globenewswire.comSalarius Granted Nasdaq Extension To Regain Compliance With Listing StandardsJune 18, 2025 | nasdaq.comSalarius Pharmaceuticals faces Nasdaq delisting over rule breachesApril 27, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEMMA, SLRX, LIPO, and IBIO Company DescriptionsEmmaus Life Sciences OTCMKTS:EMMA$0.01 0.00 (-9.17%) As of 08/29/2025 02:25 PM EasternEmmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.iBio NYSE:IBIO$0.82 -0.01 (-0.90%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.80 -0.02 (-2.65%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.Lipella Pharmaceuticals NASDAQ:LIPO$0.59 0.00 (-0.51%) As of 08/29/2025 02:43 PM EasternLipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.Salarius Pharmaceuticals NASDAQ:SLRX$5.76 +0.08 (+1.41%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$5.64 -0.13 (-2.17%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
